Myocardial growth before and after birth: clinical implications.
Perinatal changes in myocardial growth have recently evoked considerable interest with regard to cardiac chamber development with congenital cardiac lesions and to myocardial development in preterm infants. It is suggested that cardiac chamber development is influenced by blood flow. Experimental pulmonary stenosis in fetal lambs may induce either greatly reduced or markedly increased right ventricular volume. Ventricular enlargement appears to be associated with a large ventricular volume load resulting from tricuspid valve regurgitation. A small competent tricuspid valve is associated with reduced flow through the ventricle due to outflow obstruction and a small right ventricle. Postnatal growth of the ventricles in congenital heart disease is discussed. Increase in myocardial mass prenatally is achieved by hyperplasia, both during normal development and when myocardial mass is increased by right ventricular outflow obstruction. Postnatally, increases in myocardial mass with normal growth, as well as with ventricular outflow obstruction, are largely due to hypertrophy of myocytes. Myocardial capillary numbers do not increase in proportion with myocyte numbers in ventricular myocardium in association with outflow obstruction. The postnatal effects of these changes in congenital heart lesions are considered. Studies in fetal lambs suggest that the late gestational increase in blood cortisol concentrations is responsible for the change in the pattern of myocardial growth after birth. The concern is raised that prenatal exposure of the premature infant to glucocorticoids, administered to the mother to attempt to prevent hyaline membrane disease in the infant, may inhibit myocyte proliferation and result in a heart with fewer than normal myocytes. This would necessitate that each myocyte would have to hypertrophy abnormally to achieve a normal cardiac mass postnatally.
Rudolph
A M
AM
Department of Pediatrics, University of California, San Francisco 94143, USA.
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000818:Animals; D002657:Child Development; D005314:Embryonic and Fetal Development / Q000502:physiology; D005260:Female; D006321:Heart / Q000187:drug effects / Q000196:embryology* / Q000254:growth & development*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D009206:Myocardium / Q000166:cytology; D011247:Pregnancy; D012680:Sensitivity and Specificity; D012756:Sheep; D013045:Species Specificity
D000305:Adrenal Cortex Hormones